The pharmacoeconomics of acne treatment: Where are we heading?

Journal of Dermatological Treatment

Volumn 19, Issue 1, 2008, Pages 27-37

  Inglese, Marc J ^a   Fleischer Jr , Alan B ^a   Feldman, Steven R ^a   Balkrishnan, Rajesh ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cost; Dermatology; Health services research; Skin disease

Indexed keywords

ANTIBIOTIC AGENT; ISOTRETINOIN; LYMECYCLINE; MINOCYCLINE;

ACNE; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; MEDLINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION ROUTES; DRUG RESISTANCE, BACTERIAL; HUMANS; MANAGED CARE PROGRAMS; MODELS, ECONOMIC;

EID: 39149120812     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701729895     Document Type: Review

References (62)

1. Bergfield WF. The evaluation and management of acne: Economic considerations. J Am Acad Dermatol. 1995;32:S52-6.
2. Stern RS. Acne therapy: Medication use and sources of care in office-based practice. Arch Dermatol. 1996;132:776-80.
3. Maddin WS, Landells IDM. Treatment of acne vulgaris and prevention of acne scarring: Canadian Consensus Guidelines. J Cutan Med Surg. 2000;4 suppl 4:2-13.
4. Krowchuk DP. Managing acne in adolescents. Pediatr Clin North Am. 2000;47:841-57.
5. Robertson J, Lang D, Hill S. Use of pharmacoeconomics in prescribing research. Part 1: Costs - moving beyond the acquisition price for drugs. J Clin Pharm Ther. 2003;28:73-9.
6. Hay J. Pharmacoeconomic guidelines: Where do we go from here? Value Health. 2001;4:211.
7. Meltzer MI. Introduction to health economics for physicians. Lancet. 2001;358:993-8.
8. Berger M. Pharmacoeconomic guidelines: Where do we go from here? Value Health. 2001;4:278 (letter).
9. Rodriguez-Monguio R, Otero M, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics. 2003;21:623-50.
10. Briggs A. Handling uncertainty in economic evaluation. BMJ. 1999;319:120.
11. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses. A review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000;283:2116-21.
12. Newby D, Hill S. Use of pharmacoeconomics in prescribing research. Part 2: Cost-minimization analysis - when are two therapies equal? J Clin Pharm Ther. 2003;28:145-50.
13. Lopert R, Lang DL, Hill SR. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis - a technique for decision-making at the margin. J Clin Pharm Ther. 2003;28:243-9.
14. Brinsmead R, Hill S. Use of pharmacoeconomics in prescribing research. Part 4: Is cost-utility analysis a useful tool? J Clin Pharm Ther. 2003;28:339-46.
15. Dolan P, Gudex C, Kind P, Williams A. Valuing health states: A comparison of methods. J Health Econ. 1996;15:209-31.
16. Chiou CF, Hay JW, Wallace JF, Bloom BS, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41:32-44.
17. Stern RS, Pass TM, Komaroff AL. Topical versus systemic agent treatment for papulopustular acne: A cost-effective analysis. Arch Dermatol. 1984;120:1571-8.
18. Cunliffe WJ, Gray JA, Macdonald-Hull S, Hughes BR, et al. Cost effectiveness of isotretinoin. J Dermatolog Treat. 1991;1:285-8.
19. Simpson NB. Social and economic aspects of acne and the cost-effectiveness of isotretinoin. J Dermatolog Treat. 1993;4 suppl 2:S6-S9.
20. Warren KJ, Cruz PD Jr. Clinical outcome and cost analysis of isotretinoin versus conventional regimens in the treatment of moderate acne vulgaris in male patients. Pediatr Dermatol. 1998;15:329-31.
21. Wessels F, Anderson AN, Kropman K. The cost-effectiveness of isotretinoin in the treatment of acne. Part 3. A cost-minimization pharmaco-economic model. S Afr Med J. 1999;89:791-4.
22. Bossuyt L, Bosschaert J, Richert B, Cromphaut P, et al. Lymecycline in the treatment of acne: An efficacious, safe and cost-effective alternative to minocycline. Eur J Dermatol. 2003;13:130-5.
23. Lee ML, Cooper A. Isotretinoin: Cost-benefit study. Australas J Dermatol. 1991;32:17-20.
24. Newton JN. How cost-effective is oral isotretinoin? Dermatology. 1997;195 suppl 1:10-14; discussion 38-40.
25. Wishart J, Villiger J. Cost-benefit of isotretinoin (Roaccutane). N Z Med J. 1991;104:291-9.
26. Fleischer AB. Original unpublished work: data analysis of U.S. National Ambulatory Medical Care Survey, 2003.
27. Wert S. Identification and management of oral isotretinoin use inconsistent with product labeling. Manag Care Interface. 2003;16:41-43, 55.
28. Berwick DM. Cost-effectiveness analysis in clinical practice. Is a truce possible? Arch Dermatol. 1984;120:1569-70.
29. Tan JK. Perspectives on isotretinoin and the Canadian Consensus Guidelines on treatment of acne. Skin Therapy Lett. 2000;6:1-4.
30. Ortonne JP. Oral isotretinoin treatment policy. Do we all agree? Dermatology. 1997;195 suppl 1:34-7; discussion 38-40.
31. Wysowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: Rapid increase from 1992 through 2000. J Am Acad Dermatol. 2002;46:505-9.
32. Stern RS. Medication and medical service utilization for acne 1995-1998. J Am Acad Dermatol. 2000;43:1042-8.
33. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol. 2000;136:1231-6.
34. Koo J. The psychosocial impact of acne: Patients' perceptions. J Am Acad Dermatol. 1995;32:S26-30.
35. Simpson N. Effect of isotretinoin on the quality of life of patients with acne. Pharmacoeconomics. 1994;6:108-13.
36. Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol. 1998;139 suppl 52:34-40.
37. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: A multicenter trial. J Am Acad Dermatol. 1996;34:482-5.
38. Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol. 2003;49 suppl 3:S227-32.
39. Greenspan AH, Gilbert R, Baker MD. Cumulative irritancy potential of adapalene cream 0.1% compared to adapalene gel 0.1% and several tretinoin formulas. Poster presentation at Academy 2001, The American Academy of Dermatology, July 28 to August 1, 2001, Anaheim, CA.
40. Balkrishnan R, Fleischer AB Jr, Paruthi S, Feldman SR. Physicians underutilize topical retinoids in the management of acne vulgaris: Analysis of US National Practice Data. J Dermatolog Treat. 2003;14:172-6.
41. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: A report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49:S1-37.
42. Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol. 1989;14:194-8.
43. Newton JN, Mallon E, Klassen A, Ryan TJ, Finlay AY. The effectiveness of acne treatment: An assessment by patients of the outcome of therapy. Br J Dermatol. 1997;137:563-7.
44. Brown GC, Sharma S, Brown MM, Garrett S. Evidence-based medicine and cost-effectiveness. J Health Care Finance. 1999;26:14-23.
45. Anell A, Norinder A. Health outcome measures used in cost-effectiveness studies: A review of original articles published between 1986 and 1996. Health Policy. 2000;51:87-99.
46. Raisch DW. Understanding quality-adjusted life years and their application to pharmacoeconomic research. Ann Pharmacother. 2000;34:906-14.
47. Girman CJ, Hartmaier S, Thiboutot D, et al. Evaluating health-related quality of life in patients with facial acne: Development of a self-administered questionnaire for clinical trials. Qual Life Res. 1996;5:481-90.
48. Anderson R, Rajagopalan R. Responsiveness of the Dermatology-specific Quality of Life (DSQL) instrument to treatment for acne vulgaris in a placebo-controlled clinical trial. Qual Life Res. 1998;7:723-34.
49. Finlay AY, Khan. , GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-16.
50. Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: Reliability, validity, and responsiveness. J Invest Dermatol. 1996;107:707-13.
51. Agency for Healthcare Research and Quality, Management of acne. Summary - Evidence Report/Technology Assessment: Number 17. AHRQ Publication No. 01-E018. Rockville, MD: Agency for Healthcare Research and Quality; March 2001.
52. Cunliffe WJ. Acne and unemployment. Br J Dermatol. 1986;115:386.
53. Eady EA. Bacterial resistance in acne. Dermatology. 1998;196:59-66.
54. Ross JL, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: Lessons from Europe. Br J Dermatol. 2003;148:467-78.
55. Coates P, Adams CA, Cunliffe WJ, McGinley KT, et al. Does oral isotretinoin prevent Propionibacterium acnes resistance? Dermatology. 1997;195 suppl 1:S4-9.
56. Gollnick HP, Krautheim A. Topical treatment in acne: Current status and future aspects. Dermatology. 2003;206:29-36.
57. Siegel JE, Torrance GW, Russell LB, Luce BR, et al. Guidelines for pharmacoeconomic studies: Recommendations from the panel on cost effectiveness in health and medicine. Pharmacoeconomics. 1997;11:150-68.
58. Wirtzer AS. Treatment of acne in the fee-for-service and managed care settings. J Am Acad Dermatol. 1995;32:S49-51.
59. McConnell RC, Fleischer AB Jr, Williford PM, Feldman SR. Most topical tretinoin treatment is for acne vulgaris through the age of 44 years: An analysis of the National Ambulatory Medical Care Survey, 1990-1994. J Am Acad Dermatol. 1998;38:221-6.
60. Yonkosky DM, Pochi PE. Acne vulgaris in childhood. Pathogenesis and management. Dermatol Clin. 1986;4:127-36.
61. Feldman SR, Fleischer AB Jr, Chen GJ. Is prior authorization of topical tretinoin for acne cost effective? Am J Manag Care. 1999;5:457-63.
62. Avorn J. Balancing the cost and value of medications: The dilemma facing clinicians. Pharmacoeconomics. 2002;20 suppl 3:S67-72.